Analysts expect Atara Biotherapeutics (NASDAQ:ATRA) to report earnings of ($0.91) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.85) and the lowest estimate coming in at ($0.96). Atara Biotherapeutics posted earnings per share of ($0.88) in the same quarter last year, which indicates a negative year over year growth rate of 3.4%. The company is scheduled to issue its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Atara Biotherapeutics will report full-year earnings of ($3.62) per share for the current fiscal year, with EPS estimates ranging from ($3.75) to ($3.49). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.84) per share, with EPS estimates ranging from ($4.27) to ($3.41). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($1.15).
In related news, EVP Mitchall G. Clark sold 22,400 shares of the company’s stock in a transaction that occurred on Thursday, March 29th. The shares were sold at an average price of $40.07, for a total transaction of $897,568.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Carol Giltner Gallagher sold 1,183 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $46.50, for a total transaction of $55,009.50. Following the sale, the director now owns 111,286 shares in the company, valued at $5,174,799. The disclosure for this sale can be found here. Insiders have sold a total of 315,324 shares of company stock worth $11,379,838 over the last 90 days. 16.20% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in the stock. Carillon Tower Advisers Inc. purchased a new stake in Atara Biotherapeutics in the 4th quarter worth approximately $23,284,000. Bridger Management LLC lifted its stake in Atara Biotherapeutics by 57.3% in the 4th quarter. Bridger Management LLC now owns 2,598,599 shares of the biotechnology company’s stock worth $47,035,000 after purchasing an additional 946,086 shares in the last quarter. Artal Group S.A. lifted its stake in Atara Biotherapeutics by 66.7% in the 4th quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock worth $18,100,000 after purchasing an additional 400,000 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in Atara Biotherapeutics by 13.4% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 3,146,820 shares of the biotechnology company’s stock worth $56,957,000 after purchasing an additional 371,099 shares in the last quarter. Finally, Nexthera Capital LP purchased a new stake in Atara Biotherapeutics in the 4th quarter worth approximately $5,188,000. Institutional investors own 76.88% of the company’s stock.
Shares of Atara Biotherapeutics stock traded down $0.85 on Friday, reaching $35.60. 117,193 shares of the company traded hands, compared to its average volume of 1,035,141. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $49.90. The company has a market capitalization of $1,450.15, a P/E ratio of -8.88 and a beta of 2.55.
COPYRIGHT VIOLATION WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3335622/zacks-brokerages-anticipate-atara-biotherapeutics-atra-to-announce-0-91-earnings-per-share.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.